Back to Search
Start Over
Cardiovascular benefits of SGLT2 inhibition in diabetes and chronic kidney diseases.
- Source :
-
Acta Physiologica . Apr2018, Vol. 222 Issue 4, p1-1. 4p. 1 Diagram. - Publication Year :
- 2018
-
Abstract
- An editorial is presented, in which the author discusses cardiovascular benefits of sodium-glucose cotransporter 2 (SGLT2) inhibition in diabetes and chronic kidney diseases. It mentions SGLT2 inhibitors attenuate postprandial increases in blood glucose by targeting its reabsorption along the early proximal tubule and enhancing urinary glucose excretion. It also mentions haemodynamics and tubular transport of SGLT2 inhibitors.
Details
- Language :
- English
- ISSN :
- 17481708
- Volume :
- 222
- Issue :
- 4
- Database :
- Academic Search Index
- Journal :
- Acta Physiologica
- Publication Type :
- Academic Journal
- Accession number :
- 128708246
- Full Text :
- https://doi.org/10.1111/apha.13050